--To the press -
Started providing solutions that provide diagnosis and medical care support from medical information such as FRONTEO and electronic medical records.
Masahiro Morimoto, President and CEO
東京 都 港区 港 南 2-12-23
(Code number: 2158 TSE Mothers)
FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) comprehensively provides screening for latent diseases, prognosis prediction, diagnosis and medical care support based on medical information such as electronic medical records. We have started to provide the solution to be done.
In recent years, efforts to utilize vast amounts of diverse medical information, including personal health records (PHR: various information on personal health, medical care, and medication) to maintain health and receive appropriate medical care, have been attracting attention. ..In addition, the government is promoting digital reform of society as a whole, such as aiming to establish the "Digital Agency" in September 2021, and among these, digitization in the medical field is regarded as one of the priority fields 9).
Against the backdrop of this growing need for medical information utilization, FRONTEO has come to build an automatic medical dictionary using AI and an automatic diagnosis / medical care support system.This is based on FRONTEO's unique artificial intelligence "Concept Encoder (trademark: concept encoder, reading: concept encoder)" and its expertise and experience in medical business and medical information.This system aims to improve medical care efficiency and patient treatment satisfaction by analyzing the psychological aspects of patients hidden in the text information recorded in electronic medical records.
FRONTEO will continue to contribute to the promotion of medical DX (digital transformation), standardization and efficiency, and improvement of patient QOL through the development of its own AI system.
1) Published materials of the Regulatory Reform Promotion Council from the Prime Minister's Office website "Digital Reform" (middle of page)
■ About Concept Encoder URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder (trademark: concept encoder, reading: concept encoder)" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values accumulated in the life science field.Patent registration number: Patent No. 6346367
FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, with a focus on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and OSINT from 8, and created by using AI to "turn text data into knowledge". We contribute to solving various corporate issues such as drug support, dementia diagnosis support, financial, human resources, and sales support. Listed on TSE Mothers on June 2014, 2007. January 6 Obtained a first-class medical device manufacturing and sales license (permit number: 26B2021X1).The capital is 13 thousand yen (as of March 1, 10350).
* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.